Analyst Price Target is $134.00
▲ +10.82% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $134.00, with a high forecast of $148.00 and a low forecast of $118.00. The average price target represents a 10.82% upside from the last price of $120.92.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in Krystal Biotech. This Buy consensus rating has held steady for over two years.
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.